Cara Therapeutics (CARA): a bullish outlook
Cara Therapeutics announced positive statistically significant results in a phase 2/3 trial for its drug I.V. CR845 which goal is to reduce pain caused by abdominal surgeries. Cara Therapeutics is a small-cap stock, so getting the drug approved will likely have a significant impact on the stock price.
The company is considered highly speculative at this point, but it has demonstrated sufficient progress so investors with a high-risk appetite are keeping a close eye on it.
Cara has a promising pipeline of pain and itch relief drugs that have a large market opportunity if they can gain FDA approval. The company is also working on non-opioid pain relief drugs that have fewer side effects than post-op opioid derived pain drugs currently on the market.
finstead.com/bite/Cara-Therapeutics-CARA-stock-forecast-prediction-august-1-2018
The company is considered highly speculative at this point, but it has demonstrated sufficient progress so investors with a high-risk appetite are keeping a close eye on it.
Cara has a promising pipeline of pain and itch relief drugs that have a large market opportunity if they can gain FDA approval. The company is also working on non-opioid pain relief drugs that have fewer side effects than post-op opioid derived pain drugs currently on the market.
finstead.com/bite/Cara-Therapeutics-CARA-stock-forecast-prediction-august-1-2018
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.